Stockscreener 앱 받기
1.31
5.07%
-0.07
시간 외 거래:
1.31
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks
B. Riley Adjusts Price Target on PDS Biotechnology to $5 From $7, Maintains Buy Rating - marketscreener.com
B. Riley Expects Stronger Earnings for PDS Biotechnology - Defense World
PDS Biotechnology Director Sir Richard Sykes Retires - TipRanks
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune® HPV Immunotherapy - Nasdaq
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research - MarketScreener
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Globe and Mail
Blair William & Co. IL Purchases 35,757 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDSB stock touches 52-week low at $1.12 amid market challenges - Investing.com
Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable
HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World
H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com
PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises - Investing.com
PDS Biotechnology Corp reports results for the quarter ended December 31Earnings Summary - TradingView
PDS BIOTECHNOLOGY Earnings Results: $PDSB Reports Quarterly Earnings - Nasdaq
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - MarketScreener
A Look at PDS Biotechnology's Upcoming Earnings ReportPDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotechnology Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - The Manila Times
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - The Manila Times
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - Defense World
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com Australia
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Morningstar
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
0.39%
3.66%
자본화:
|
볼륨(24시간):